Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25273685 | 0.88 | L3MBTL1 (0.48) | L3MBTL1HTTMAPTPKMBRD4 | |
| SCHEMBL31052395 | 0.88 | L3MBTL1 (0.48) | L3MBTL1HTTMAPTPKMBRD4 | |
| SCHEMBL15426836 | 0.83 | L3MBTL1 (0.53) | L3MBTL1HTTMAPTGAAPKM | |
| SCHEMBL1015374 | 0.82 | L3MBTL1 (0.52) | L3MBTL1HTTMAPTPKMBRD4 | |
| SCHEMBL4724390 | 0.81 | L3MBTL1 (0.51) | L3MBTL1HTTMAPTGAAPKM | |
| SCHEMBL4793803 | 0.80 | L3MBTL1 (0.50) | L3MBTL1HTTMAPTGAAPKM | |
| SCHEMBL31246107 | 0.80 | L3MBTL1 (0.50) | L3MBTL1HTTMAPTPKMBRD4 | |
| SCHEMBL32667901 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2HIF1AHSD17B10HTTMAPT | |
| SCHEMBL15728077 | 0.76 | L3MBTL1 (0.46) | L3MBTL1HTTMAPTGAAPKM | |
| SCHEMBL14547890 | 0.76 | FGFR4 (0.51) | SMN1; SMN2HSD17B10HTTMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20260028346-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, TEC | SMN1; SMN2 4087/4885HIF1A 4383/4885L3MBTL1 2434/4885 |
| US-20260028346-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, LYN | SMN1; SMN2 3649/4885HIF1A 4287/4885L3MBTL1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.